Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. | Dexcom said Smart Basal is the ...
Zacks Investment Research on MSN
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter.
Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
In tweaking its chatbot to appeal to more people, OpenAI made it riskier for some of them. Now the company has made its chatbot safer. Will that undermine its quest for growth? By Kashmir Hill and ...
Abstract: We address the problem of localizing an (unauthorized) transmitter using a distributed set of sensors. Our focus is on developing techniques that perform the transmitter localization in an ...
Abstract: We present a 2.4GHz ultra-low power energy-harvested narrowband transmitter (TX) for wireless sensing and biomedical devices. We used a 434 MHz RF energy for resonant cavity based wireless ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback